Albemarle stock is trading -25.36% below its average target price of $263.32 after marking a 3.6% during today's afternoon session. Analysts are giving the large-cap Chemicals company an average rating of buy and target prices ranging from $155.0 to $344.0 per share.
Albemarle has an average level of shares sold short, at 6.3% of its total share float. The stock's short ratio (also called days to cover) is 3.2. The company's insiders own 0.23% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 89.7% of Albemarle's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Albemarle
|2023-06-30||Vanguard Group Inc||12%||14,039,343||$2,759,292,378|
|2023-06-30||State Street Corporation||4%||5,242,800||$1,030,419,876|
|2023-06-30||Bank of America Corporation||4%||5,117,596||$1,005,812,283|
|2023-06-30||Capital Research Global Investors||3%||3,381,656||$664,630,647|
|2023-06-30||Franklin Resources, Inc.||3%||3,135,732||$616,296,746|
|2023-06-30||Baillie Gifford and Company||2%||2,494,230||$490,215,947|
|2023-06-30||Geode Capital Management, LLC||2%||2,481,901||$487,792,805|
|2023-06-30||Capital International Investors||2%||2,267,914||$445,735,802|
|2023-06-30||Primecap Management Company||2%||2,099,025||$412,542,359|